https://markets.businessinsider.com/news/stocks/perspective-therapeutics-announces-first-patient-dosed-with-212pb-vmt01-monotherapy-at-1-5-mci-in-a-phase-1-2a-study-of-mc1r-positive-metastatic-melanoma-1034573526
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in...
SEATTLE, April 11, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiophar...